A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Conditions
- CLLSmall-Cell LymphomaLymphoma, Small LymphocyticSLLLeukemia, Chronic LymphocyticLeukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Registration Number
- NCT05947851
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 720
- Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to initiate therapy.
- Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, immunoglobulin heavy chain gene (IGHV) mutation status and Bruton's tyrosine kinase (BTK)-C481 mutation status results required before randomization for Part 2 participants only.
- Relapsed or refractory to at least 1 prior available therapy.
- Have at least 1 marker of disease burden.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.
- Has a life expectancy of at least 3 months.
- Has the ability to swallow and retain oral medication.
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.
- Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.
- Participants with adequate organ function with specimens collected within 7 days before the start of study intervention.
- If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar): not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception.
- Participant assigned female sex at birth are eligible to participate if not pregnant or breastfeeding and are not a person of childbearing potential (POCBP) OR is a POCBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding.
- Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.
- Has gastrointestinal (GI) dysfunction that may affect drug absorption.
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.
- Has an active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening.
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease and/or acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.
- Has QT interval corrected (QTc) prolongation or other significant electrocardiogram (ECG) abnormalities.
- Has a known allergy/sensitivity to nemtabrutinib or contraindication to venetoclax/rituximab (or rituximab biosimilar), or any of the excipients.
- Has history of severe bleeding disorders (eg, hemophilia).
- Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization.
- Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) including venetoclax or Non-covalent Bruton's tyrosine kinase inhibitor (BTKi).
- Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.
- Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention.
- Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.
- Has a known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
- Participants who have not adequately recovered from major surgery or have ongoing surgical complications.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Nemtabrutinib + Venetoclax Nemtabrutinib Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 Day 1 (C2D1) up to 2 years post C2D1 or until progressive disease (PD) or discontinuation. A cycle = 4 weeks. Venetoclax + Rituximab Venetoclax Participants will receive venetoclax oral tablets at doses from 20 mg up to 400 mg daily starting at C1D1 on 4-week cycles up to 2 years and rituximab or biosimilar at 375 mg/m\^2 up to 500 mg/m2 intravenous infusion once per 28-day cycle starting at C2D1, for 6 total cycles. Treatment will continue until progressive disease (PD) or discontinuation. Nemtabrutinib + Venetoclax Venetoclax Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 Day 1 (C2D1) up to 2 years post C2D1 or until progressive disease (PD) or discontinuation. A cycle = 4 weeks. Venetoclax + Rituximab Rituximab Participants will receive venetoclax oral tablets at doses from 20 mg up to 400 mg daily starting at C1D1 on 4-week cycles up to 2 years and rituximab or biosimilar at 375 mg/m\^2 up to 500 mg/m2 intravenous infusion once per 28-day cycle starting at C2D1, for 6 total cycles. Treatment will continue until progressive disease (PD) or discontinuation.
- Primary Outcome Measures
Name Time Method Part 2: PFS per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as assessed by Blinded Independent Central Review (BICR) Up to approximately 71 months PFS is defined as the time from randomization to the first documented disease progression per iwCLL criteria 2018 as accessed by BICR, or death due to any cause, whichever occurs first. PFS will be presented.
Part 1: Number of participants experiencing adverse events (AEs) Up to approximately 28 months An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs) Up to approximately 12 Weeks DLT evaluation period is defined as 8 weeks after the first dose of the combination treatment of nemtabrutinib plus venetoclax Cycle 2 Day 1 in Part 1 + 4 weeks follow up. Each cycle is 4 weeks. DLTs are: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting \>7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for \>1 week (with exceptions); missing \>25% of nemtabrutinib or venetoclax doses as a result of drug-related adverse events during the first 2 cycles; Grade 5 toxicity.
Part 1: Number of participants discontinuing study treatment due to AEs Up to approximately 25 months An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to AEs will be reported for Part 1.
- Secondary Outcome Measures
Name Time Method Part 2: Undetectable minimal residual disease (MRD) rate in bone marrow as assessed by central laboratory Month 14 Undetectable MRD, defined as \<1 leukemic cell per 10,000 cells (MRD \<10-4) in bone marrow. The MRD rate will be presented.
Part 2: Overall Survival (OS) Up to approximately 108 months OS, defined as the time from randomization to death due to any cause. OS will be presented.
Part 2: Number of participants discontinuing study treatment due to AEs Up to approximately 25 months An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to AEs will be reported for Part 2.
Part 2: Duration of Response (DOR) per iwCLL Criteria 2018 as assessed by BICR Up to approximately 108 months DOR, defined as the time from the first documented evidence of CR, CRi, nPR, or PR that led to response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes \>1.5 cm, spleen size \<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10\^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10\^9/L or ≥50% increase from screening, hemoglobin \>11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. DOR will be presented.
Part 2: Objective Response Rate (ORR) per iwCLL Criteria 2018 as assessed by BICR Up to approximately 108 months OR, defined as complete response/remission (CR), complete response with incomplete count recovery (CRi), nodular partial remission (nPR), or partial remission (PR). CR is defined as meeting the following criteria: no lymph nodes \>1.5 cm, spleen size \<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10\^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10\^9/L or ≥50% increase from screening, hemoglobin \>11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. ORR will be presented.
Part 2: Number of participants experiencing AEs Up to approximately 28 months An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.
Trial Locations
- Locations (109)
Memorial Hospital West ( Site 5410)
🇺🇸Pembroke Pines, Florida, United States
Oregon Health and Science University ( Site 5425)
🇺🇸Portland, Oregon, United States
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308)
🇧🇷Sao Paulo, Brazil
The Moncton Hospital ( Site 1414)
🇨🇦Moncton, New Brunswick, Canada
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 1402)
🇨🇦Greenfield Park, Quebec, Canada
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer
🇨🇦Sherbrooke, Quebec, Canada
Biocenter ( Site 1507)
🇨🇱Concepcion., Biobio, Chile
IC La Serena Research ( Site 1506)
🇨🇱La Serena., Coquimbo, Chile
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509)
🇨🇱Santiago, Region M. De Santiago, Chile
Universitätsklinikum Leipzig-Medical Department I - Hematology and Celltherapy ( Site 2201)
🇩🇪Leipzig, Sachsen, Germany
Rambam Health Care Campus ( Site 2801)
🇮🇱Haifa, Israel
Sheba Medical Center-Hemato Oncology ( Site 2809)
🇮🇱Ramat Gan, Israel
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant
🇮🇹Alessandria, Italy
Ospedale San Raffaele-Programma di Ricerca Strategica sulla LLC ( Site 2902)
🇮🇹Milano, Italy
Arcispedale Santa Maria Nuova-Hematology ( Site 2900)
🇮🇹Reggio Emilia, Italy
Auxilio Mutuo Cancer Center ( Site 3900)
🇵🇷San Juan, Puerto Rico
Namik Kemal University Medical Faculty-Hematology ( Site 4912)
🇹🇷Tekirdag, Tekirdas, Turkey
Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 4913)
🇹🇷Ankara, Turkey
Mega Medipol-Hematology ( Site 4904)
🇹🇷İstanbul, Turkey
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4906)
🇹🇷Istanbul, Turkey
Ege Universitesi Hastanesi ( Site 4902)
🇹🇷İzmir, Turkey
City Hospital, Nottingham University Hospitals-Hematology ( Site 5002)
🇬🇧Nottingham, England, United Kingdom
University College London Hospital-Cancer Clinical Trials Unit ( Site 5001)
🇬🇧London-Camden, London, City Of, United Kingdom
Highlands Oncology Group ( Site 5405)
🇺🇸Springdale, Arkansas, United States
MemorialCare Health System - Long Beach Medical Center ( Site 5421)
🇺🇸Long Beach, California, United States
Centre Hospitalier Universitaire Estaing ( Site 2105)
🇫🇷Clermont-Ferrand, Puy-de-Dome, France
CHD Vendee ( Site 2100)
🇫🇷La Roche-sur-Yon, Vendee, France
Klinikum Mutterhaus der Borromäerinnen-Innere Medizin I ( Site 2203)
🇩🇪Trier, Rheinland-Pfalz, Germany
Hadassah Medical Center-Hemato-Oncology ( Site 2812)
🇮🇱Jerusalem, Israel
Centro de Infusion Superare ( Site 3314)
🇲🇽Ciudad de México, Distrito Federal, Mexico
Health Pharma Professional Research S.A. de C.V: ( Site 3301)
🇲🇽Ciudad de México, Distrito Federal, Mexico
Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 4401)
🇿🇦Moreletta Park, Gauteng, South Africa
Groote Schuur Hospital ( Site 4400)
🇿🇦Cape Town, Western Cape, South Africa
Haemalife ( Site 4407)
🇿🇦Kuilsriver, Western Cape, South Africa
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4601)
🇪🇸L'Hospitalet Del Llobregat, Barcelona, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 4602)
🇪🇸Pozuelo de Alarcon, Madrid, Spain
HOSPITAL CLINICO DE VALENCIA-HEMATOLOGY ( Site 4603)
🇪🇸Valencia, Valenciana, Comunitat, Spain
Medical Oncology Associates, PS ( Site 5406)
🇺🇸Spokane, Washington, United States
Instituto Alexander Fleming ( Site 1005)
🇦🇷Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423)
🇺🇸Madison, Wisconsin, United States
Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007)
🇦🇷Mar del Plata, Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Hematology ( Site 1002)
🇦🇷Buenos Aires, Caba, Argentina
Sanatorio Parque ( Site 1003)
🇦🇷Rosario, Santa Fe, Argentina
Centro Medico Fleischer ( Site 1006)
🇦🇷Buenos Aires, Argentina
Hospital Aleman-oncohematologic diseases ( Site 1001)
🇦🇷Buenos Aires, Argentina
Royal Adelaide Hospital ( Site 1104)
🇦🇺Adelaide, South Australia, Australia
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103)
🇦🇺Melbourne, Victoria, Australia
UZ Leuven-Hematology ( Site 1200)
🇧🇪Leuven, Vlaams-Brabant, Belgium
ZAS Cadix ( Site 1203)
🇧🇪Antwerpen, Belgium
FALP-UIDO ( Site 1500)
🇨🇱Santiago, Region M. De Santiago, Chile
Clínica Inmunocel ( Site 1511)
🇨🇱Santiago, Region M. De Santiago, Chile
Fundación Valle del Lili ( Site 1703)
🇨🇴Cali, Valle Del Cauca, Colombia
Hopital Claude Huriez - CHU de Lille ( Site 2107)
🇫🇷Lille, Nord, France
Sourasky Medical Center ( Site 2811)
🇮🇱Tel Aviv, Israel
Highlands Oncology Group ( Site 5405)
🇺🇸Springdale, Arkansas, United States
MemorialCare Health System - Long Beach Medical Center ( Site 5421)
🇺🇸Long Beach, California, United States
Memorial Hospital West ( Site 5410)
🇺🇸Pembroke Pines, Florida, United States
Oregon Health and Science University ( Site 5425)
🇺🇸Portland, Oregon, United States
Medical Oncology Associates, PS ( Site 5406)
🇺🇸Spokane, Washington, United States
University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423)
🇺🇸Madison, Wisconsin, United States
Instituto Alexander Fleming ( Site 1005)
🇦🇷Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007)
🇦🇷Mar del Plata, Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Hematology ( Site 1002)
🇦🇷Buenos Aires, Caba, Argentina
Sanatorio Parque ( Site 1003)
🇦🇷Rosario, Santa Fe, Argentina
Centro Medico Fleischer ( Site 1006)
🇦🇷Buenos Aires, Argentina
Hospital Aleman-oncohematologic diseases ( Site 1001)
🇦🇷Buenos Aires, Argentina
Royal Adelaide Hospital ( Site 1104)
🇦🇺Adelaide, South Australia, Australia
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103)
🇦🇺Melbourne, Victoria, Australia
UZ Leuven-Hematology ( Site 1200)
🇧🇪Leuven, Vlaams-Brabant, Belgium
ZAS Cadix ( Site 1203)
🇧🇪Antwerpen, Belgium
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308)
🇧🇷Sao Paulo, Brazil
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 1410)
🇨🇦Sherbrooke, Quebec, Canada
Hopital Claude Huriez - CHU de Lille ( Site 2107)
🇫🇷Lille, Nord, France
Centre Hospitalier Universitaire Estaing ( Site 2105)
🇫🇷Clermont-Ferrand, Puy-de-Dome, France
The Moncton Hospital ( Site 1414)
🇨🇦Moncton, New Brunswick, Canada
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509)
🇨🇱Santiago, Region M. De Santiago, Chile
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 1402)
🇨🇦Greenfield Park, Quebec, Canada
Biocenter ( Site 1507)
🇨🇱Concepcion., Biobio, Chile
IC La Serena Research ( Site 1506)
🇨🇱La Serena., Coquimbo, Chile
FALP-UIDO ( Site 1500)
🇨🇱Santiago, Region M. De Santiago, Chile
Clínica Inmunocel ( Site 1511)
🇨🇱Santiago, Region M. De Santiago, Chile
CHD Vendee ( Site 2100)
🇫🇷La Roche-sur-Yon, Vendee, France
Klinikum Mutterhaus der Borromäerinnen-Innere Medizin I ( Site 2203)
🇩🇪Trier, Rheinland-Pfalz, Germany
Arcispedale Santa Maria Nuova-Hematology ( Site 2900)
🇮🇹Reggio Emilia, Italy
Fundación Valle del Lili ( Site 1703)
🇨🇴Cali, Valle Del Cauca, Colombia
Universitätsklinikum Leipzig-Medical Department I - Hematology and Celltherapy ( Site 2201)
🇩🇪Leipzig, Sachsen, Germany
Rambam Health Care Campus ( Site 2801)
🇮🇱Haifa, Israel
Hadassah Medical Center-Hemato-Oncology ( Site 2812)
🇮🇱Jerusalem, Israel
Sheba Medical Center-Hemato Oncology ( Site 2809)
🇮🇱Ramat Gan, Israel
Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2906)
🇮🇹Alessandria, Ancona, Italy
Sourasky Medical Center ( Site 2811)
🇮🇱Tel Aviv, Israel
Ospedale San Raffaele-Programma di Ricerca Strategica sulla LLC ( Site 2902)
🇮🇹Milano, Italy
Centro de Infusion Superare ( Site 3314)
🇲🇽Ciudad de México, Distrito Federal, Mexico
Health Pharma Professional Research S.A. de C.V: ( Site 3301)
🇲🇽Ciudad de México, Distrito Federal, Mexico
Centro de Investigacion Clinica Chapultepec ( Site 3309)
🇲🇽Morelia, Michoacan, Mexico
Auxilio Mutuo Cancer Center ( Site 3900)
🇵🇷San Juan, Puerto Rico
HOSPITAL CLINICO DE VALENCIA-HEMATOLOGY ( Site 4603)
🇪🇸Valencia, Valenciana, Comunitat, Spain
Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 4401)
🇿🇦Moreletta Park, Gauteng, South Africa
Groote Schuur Hospital ( Site 4400)
🇿🇦Cape Town, Western Cape, South Africa
Namik Kemal University Medical Faculty-Hematology ( Site 4912)
🇹🇷Tekirdag, Tekirdas, Turkey
Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 4913)
🇹🇷Ankara, Turkey
Mega Medipol-Hematology ( Site 4904)
🇹🇷İstanbul, Turkey
Haemalife ( Site 4407)
🇿🇦Kuilsriver, Western Cape, South Africa
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 4602)
🇪🇸Pozuelo de Alarcon, Madrid, Spain
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4601)
🇪🇸L'Hospitalet Del Llobregat, Barcelona, Spain
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4906)
🇹🇷Istanbul, Turkey
Ege Universitesi Hastanesi ( Site 4902)
🇹🇷İzmir, Turkey
City Hospital, Nottingham University Hospitals-Hematology ( Site 5002)
🇬🇧Nottingham, England, United Kingdom
University College London Hospital-Cancer Clinical Trials Unit ( Site 5001)
🇬🇧London-Camden, London, City Of, United Kingdom